Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993120 · ClinicalTrials.gov registry record
Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States
A clinical trial, sponsored by Amgen.
- Completed
- Registry status
- 5,006
- Enrollment target
NCT02993120: Completed study, sponsored by Amgen.
NCT02993120 is a clinical trial that has completed, run by Amgen. The registered enrollment target is 5,006 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02993120 has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 5,006 participants
- Enrollment target
Study Summary
This is a multicenter observational cohort study with both retrospective and prospective data collection components in subjects with ASCVD. The purpose of this study is to better understand cholesterol treatment patterns in the context of a changing landscape in subjects with ASCVD.
Primary Outcome
Describe low-density lipoprotein (LDL) treatment patterns over time in subjects with clinical ASCVD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,006 participants |
| Start Date | 2016-12-06 |
| Est. Completion | 2021-08-06 |
What the finished NCT02993120 record still lists
NCT02993120 is an observational study that tracks outcomes without assigning an intervention. Its 5,006 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02993120 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02993120 about?
NCT02993120 is a clinical study titled "Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States". This is a multicenter observational cohort study with both retrospective and prospective data collection components in subjects with ASCVD. The purpose of this study is to better understand cholesterol treatment patterns in the context of a changing landscape in subjects with ASCVD.
What is the current status of trial NCT02993120?
This trial is currently completed. The enrollment target is 5,006 participants. The study started on 2016-12-06. Estimated completion is 2021-08-06.
Who is sponsoring clinical trial NCT02993120?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743362 · 5,010 participants
A Study of Noninvasive Methods to Evaluate Skin and Mucosal Conditions
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI